CD276 and Familial prostate cancer: We determined that B7H3 is expressed across a diverse spectrum of late-stage treatment-resistant mPC genotypes and phenotypes as well as across metastatic sites, which extends prior analyses of B7H3 in prostate cancer (7–9, 28).